



(Company Registration Number: 198403368H)

Condensed interim financial statements for
The second quarter ended 30 June 2025 ("1H2025") and
Six months ended 30 June 2025 ("6M2025")

*This announcement has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are:

Name: Mr. Jerry Chua, (Registered Professional, Evolve Capital Advisory Private Limited)

Address: 160 Robinson Road, SBF Center, #20-01/02, Singapore 068914

Tel: (65) 6381 6966

A Condensed interim consolidated statement of profit or loss and other comprehensive income

	Group			Group		
	3 months ended 30/06/2025 S\$'000 (Unaudited)	3 months ended 30/06/2024 S\$'000 (Unaudited)	Increase / (Decrease) %	6 months ended 30/06/2025 S\$'000 (Unaudited)	6 months ended 30/06/2024 S\$'000 (Unaudited)	Increase / (Decrease) %
<i>Continuing operations</i>						
Revenue	823	678	21.4	1,768	1,389	27.3
Cost of sales	(615)	(617)	(0.3)	(945)	(950)	0.5
Gross profit	208	61	241.0	823	439	87.5
Other operating income	18	253	(92.9)	49	294	(83.3)
Selling and distribution expenses	(139)	(261)	(46.7)	(285)	(370)	(23.0)
Administrative expenses	(749)	(685)	9.3	(1,468)	(1,498)	(2.0)
Other operating expenses	-	(2)	(100.0)	-	(5)	(100.0)
Finance costs	(15)	(13)	15.4	(31)	(22)	40.9
Loss before income tax	(677)	(647)	4.6	(912)	(1,162)	(21.5)
Income tax credit	-	14	(100.0)	1	4	(75.0)
Loss for the year presenting loss attributable to equity holders of the Company	(677)	(633)	7.0	(911)	(1,158)	(21.3)
Other comprehensive (loss)/income, net of tax:						
<i>Item that may be reclassified subsequently to profit or loss, net of tax</i>						
Exchange differences on translation of a foreign operation, net of tax	-	(2)	(100.0)	1	(1)	nm
Total comprehensive loss, for the financial period	(677)	(635)	6.6	(910)	(1,159)	(21.5)
Total comprehensive (loss)/profit attributable to:						
Equity holders of the Company	(677)	(635)	7.4	(910)	(1,159)	(15.2)
Non-controlling interest	-	-	nm	-	-	nm
	(677)	(635)	6.6	(910)	-	
Total loss per share, for the period attributable to the owners of the company						
Basic (in cents)	(0.045)	(0.051)		(0.061)	(0.094)	
Diluted (in cents)	(0.045)	(0.051)		(0.061)	(0.094)	
Weighted average number of shares used in the computation of basic and diluted loss per share (‘000)	1,502,938	1,229,485		1,502,938	1,229,485	

A Condensed interim consolidated statement of profit or loss and other comprehensive income (Cont'd)

Loss before tax is determined after crediting/(charging) the following:

	Group					
	3 months ended 30/06/2025	3 months ended 30/06/2024	Increase / (Decrease)	6 months ended 30/06/2025	6 months ended 30/06/2024	Increase / (Decrease)
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
	(Unaudited)	(Unaudited)		(Unaudited)	(Unaudited)	
Government grants	6	-	n.m	21	12	75
Liabilities written off	-	66	(100)	-	66	(100)
Reversal of accruals	-	125	(100)	-	125	(100)
Amortisation of intangible assets	(3)	(23)	(87)	(8)	(23)	(65)
Depreciation of plant and equipment	(26)	(30)	(13)	(49)	(62)	(21)
Depreciation of right-of-use assets	(84)	(62)	35	(140)	(122)	15

There are no material related party transactions apart from those disclosed in other information required by listing rule section.

B Condensed interim statements of financial position

	Group		Company	
	30/06/2025	31/12/2024	30/06/2025	31/12/2024
	S\$'000	S\$'000	S\$'000	S\$'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
NON-CURRENT ASSETS				
Plant and equipment	142	191	33	35
Right-of-use assets	1,224	1,364	93	94
Investment in subsidiaries	-	-	3,720	3,720
Intangible assets	32	40	-	-
Other non-current asset	9	9	-	-
Other receivables	62	62	-	-
	1,469	1,666	3,846	3,849
CURRENT ASSETS				
Inventories	1,099	1,238	24	24
Trade and other receivables	1,305	992	983	1,006
Cash and cash equivalents	114	8	1	- *
	2,538	2,238	1,008	1,030
Total Assets	3,987	3,904	4,854	4,879
CURRENT LIABILITIES				
Lease liabilities	156	259	37	37
Deferred consideration	92	92	-	-
Trade and other payables	3,618	2,819	2,237	1,734
Amount due to directors	116	190	-	85
Provision for other liabilities	-	-	-	-
	3,982	3,360	2,374	1,856
NON-CURRENT LIABILITIES				
Provision for reinstatement costs	77	77	-	-
Loan and borrowings	500	500	500	807
Loan from a director	774	399	682	-
Lease liabilities	1,022	1,024	65	67
Deferred tax liabilities	5	7	-	-
	2,378	2,007	1,247	874
Total Liabilities	6,360	5,367	3,621	2,730
Net current liabilities	(1,464)	(1,122)	(1,366)	(826)
Net (liabilities)/assets	(2,373)	(1,463)	1,233	2,149
EQUITY				
Share Capital	46,364	46,364	46,364	46,364
Accumulated losses	(48,855)	(47,944)	(45,131)	(44,215)
Foreign currency translation reserve	1	-	-	-
Attributable to equity holders of the Company	(2,490)	(1,580)	1,233	2,149
Non-controlling interest	117	117	-	-
Total Equity	(2,373)	(1,463)	1,233	2,149

*Less than \$1,000

Aggregate amount of Group's borrowings and debt securities:

	Group		Company	
	30/06/2025	31/12/2024	30/06/2025	31/12/2024
	S\$'000	S\$'000	S\$'000	S\$'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<u>Unsecured</u>				
Term loan	-	-	-	-
Loan from a key management personal	500	500	500	807
Loan from a director	774	399	682	-
	<u>1,274</u>	<u>899</u>	<u>1,182</u>	<u>807</u>
<u>Disclosed as:-</u>				
Non-current	1,274	899	1,182	807
Current	-	-	-	-
	<u>1,274</u>	<u>899</u>	<u>1,182</u>	<u>807</u>

Loan from key management personnel and loan from a director are unsecured, non-interest bearing and not due to paid within one year.

C Condensed interim statements of changes in equity

The Group	Share Capital S\$'000	Accumulated Losses S\$'000	Foreign Currency translation reserve S\$'000	Total S\$'000	Non- controlling interest S\$'000	Total equity S\$'000
2025						
Balance at 1 January 2025	46,364	(47,944)	-	(1,580)	117	(1,463)
Loss for the year	-	(911)	-	(911)	-	(911)
<u>Other comprehensive loss for the financial period</u>						
Foreign currency translation	-	-	1	1	-	1
Other comprehensive reserve	-	-	-	-	-	-
Total comprehensive loss for the financial period	-	(911)	1	(910)	-	(910)
Balance at 30 June 2025	46,364	(48,855)	1	(2,490)	117	(2,373)
2024						
Balance at 1 January 2024	42,745	(44,079)	1	(1,333)	117	(1,216)
Issuance of new ordinary shares	2,991	-	-	2,991	-	2,991
Share issue expenses	(121)	-	-	(121)	-	(121)
Loss for the financial period	-	(1,158)	-	(1,158)	-	(1,158)
<u>Other comprehensive loss for the financial period</u>						
Foreign currency translation	-	-	(2)	(2)	-	(2)
Total comprehensive loss for the financial period	-	(1,158)	(2)	(1,160)	-	(1,160)
Balance at 30 June 2024	45,615	(45,237)	(1)	377	117	494

C Condensed interim statements of changes in equity (Cont'd)

The Company	Share Capital capital S\$'000	Accumulated Losses S\$'000	Total equity S\$'000
2025			
Balance at 1 January 2025	46,364	(44,215)	2,149
Loss for the financial period	-	(916)	(916)
Total comprehensive loss for the financial period	-	(916)	(916)
Balance at 30 June 2025	46,364	(45,131)	1,233
2024			
Balance at 1 January 2024	42,745	(41,974)	771
Issuance of new ordinary shares	2,991	-	2,991
Share issue expenses	(121)	-	(121)
Loss for the financial period	-	(909)	(909)
Total comprehensive loss for the financial period	-	(909)	(909)
Balance at 30 June 2024	45,615	(42,883)	2,732

D Condensed interim consolidated statement of cash flows

	Group		Group	
	3 months ended	3 months ended	6 months ended	6 months ended
	30/06/2025	30/06/2024	30/06/2025	30/06/2024
	Unaudited	Unaudited	Unaudited	Unaudited
	S\$'000	S\$'000	S\$'000	S\$'000
Cash flow from operating activities				
Loss before tax	(677)	(400)	(912)	(1,162)
<u>Adjustments for:</u>				
Depreciation of plant and equipment	26	29	49	61
Depreciation of right-of-use assets	84	62	140	122
Amortisation of intangible assets	3	23	8	23
Interest expense on lease liabilities	15	13	31	22
Gain on lease modification	-	(1)	-	-
Operating loss before working capital changes	(549)	(274)	(684)	(935)
<u>Changes in working capital:</u>				
Inventories	84	(195)	139	(275)
Trade and other receivables	109	(128)	(313)	(407)
Trade and other payables	280	(29)	625	219
Net cash used in operations	(76)	(626)	(233)	(1,398)
Income tax paid	-	(13)	-	(22)
Net cash used in operating activities	(76)	(639)	(233)	(1,420)
Cash flows from financing activities				
Payment of principal portion of lease liabilities	(56)	(54)	(105)	(109)
Payment of interest portion of lease liabilities	-	-	(31)	-
Amount due to directors	(464)	-	-	-
Proceeds from loan from a director, net of repayment	475	-	475	-
Proceeds from loan and borrowings	-	500	-	500
Issuance of new ordinary shares, net of share issue expenses	-	-	-	707
Net cash (used in)/generated from financing activities	(41)	446	339	1,098
Net (decrease)/increase in cash and cash equivalents	(136)	(193)	106	(322)
Cash and cash equivalents at beginning of financial period	250	281	8	409
Effect of currency translation on cash and cash equivalents	-	(2)	-	(1)
Cash and cash equivalents at end of the financial period	114	86	114	86

1. Corporate information

AJJ Medtech Holdings Limited (the “**Company**”) (Registration No. 198403368H) is incorporated and domiciled in Singapore as a limited liability company and is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”).

The registered office and principal place of business of the Company is located at 8 Commonwealth Lane, #02-04 Grande Building, Singapore 149555.

The condensed interim consolidated financial statements as at and for the twelve months period ended 31 December 2024 comprise the Company and its subsidiaries (collectively known as the “**Group**”).

The principal activities of the Group are investment holding and the provision of integrated medtech solutions to healthcare facilities. The principal activities of the subsidiaries are:

- (a) Investment holding of healthcare technologies and services;
- (b) Provide supply chain solutions to public health institutes, including advanced medical devices and equipment, advanced medical technology development including digital solutions, and technology development;
- (c) Conduct research and development of medical technologies, manufacture and repair of irradiation and electromedical devices such as HIFU machines and other medical equipment;
- (d) Development of and distribution of:
 - (i) devices and equipment for use in the healthcare and medical industries that are primarily driven by, or enhanced or integrated with, digital tools, artificial intelligence (AI), and robotics and other medical technologies;
 - (ii) systems, solutions and applications (in software form or otherwise) that are based on or driven by digital tools, AI, robotics and other medical technologies that may be used in the healthcare and medical industries; and
- (e) Childcare wellness enhancement education material.

2. Basis of preparation

The condensed interim consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company for the six months ended 30 June 2025 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the financial year ended 31 December 2024.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The financial statements are presented in Singapore Dollars (SGD or S\$), which is the functional currency of the Company. All values are rounded to the nearest thousand (S\$’000), except when otherwise indicated.

2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2. Use of judgements and estimates

The preparation of the condensed interim financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future period affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in material adjustment to the carrying amounts of assets and liabilities within the next interim period are included below:

i) Impairment on investment in subsidiaries

The recoverable amount of the investment is reviewed at the end of each reporting period to determine whether there is any indication that the investment has suffered an impairment loss. If any such indication exists, the carrying amount of the investment is determined on the basis of the net recoverable amount to determine the extent of the impairment loss.

ii) Leases – estimating the incremental borrowing rate

The Group cannot readily determine the interest rate implicit in the lease, therefore it uses incremental borrowing rate to measure lease liabilities. The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate therefore reflects what the Group 'would have to pay', which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Group estimates the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

iii) Impairment assessment on non-financial assets

An assessment is made for the reporting year whether there is any indication that the asset may be impaired. If any such indication exists, an estimate is made of the recoverable amount of the asset. The recoverable amounts of cash-generating units if applicable is measured based on the fair value less costs of disposal or value in use calculations. It is reasonably possible, based on existing knowledge, that outcomes within the next reporting year that are different from assumptions could require a material adjustment to the carrying amount of the balances affected.

iv) Provision for Expected Credit Losses ("ECLs") of trade and other receivables

The Group determines the expected credit loss for trade and other receivables based on assumptions about risk of default and expected credit loss rate. The Group adopts judgement in making these assumptions and selecting inputs for computing such impairment loss, broadly based on the available customer's historical data, like ageing analysis of the receivables, creditworthiness and the past collection history of each customer, existing market conditions and forward-looking estimates at end of each reporting date.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment information

(a) *Products and services from which reportable segments derive their revenues*

The Group operates in the following segments:

1. Corporate and Healthcare wellness education;
2. Healthcare digital products;
3. Healthcare products and services; and

Segment revenue represents revenue generated from external customers. Segment results represent the profit/(loss) earned/(incurred) by each segment without allocation of interest income, finance costs and income tax expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

For the purpose of monitoring segment performance and allocating resources between segments, the chief operating decision maker monitors the tangible assets and financial assets attributable to each segment.

4. Segment information (Cont'd)

(b) Segment revenues and results

<i>Group Segment revenues</i>	6 months ended			
	30/06/2025		30/06/2024	
	Revenue		Revenue	
	S\$'000	%	S\$'000	%
Corporate and Healthcare wellness education	314	17.8	-	-
Healthcare digital products	-	-	3	0.2
Healthcare products and services	1,454	82.2	1,386	99.8
	1,768	82.2	1,389	100.0
Timing of transfer of goods or services:				
At a point in time	1,768		1,389	

<i>Group Segment results</i>	6 months ended			
	30/06/2025		30/06/2024	
	Results		Results	
	S\$'000	%	S\$'000	%
Corporate and Healthcare wellness education	(924)	101.4	(909)	78.5
Healthcare digital products	-	-	(1)	0.1
Healthcare products and services	13	(1.4)	(248)	21.4
	(911)	100.0	(1,158)	100.0

The Group's revenue for the 6 months' period ended 30 June 2025 was derived from sales of healthcare products and services, and sales of childcare wellness education material, all of which operate in Singapore. There were no inter-segment sales during the periods ended 30 June 2025 and 30 June 2024.

4. Segment information (Cont'd)

(c) Segment assets and liabilities

As at 30 June 2025 and 31 December 2024, the allocation of the Group's total assets and liabilities to the reportable segments are as follows:

	Corporate and Healthcare wellness education	Healthcare digital products	Healthcare products and services	Total
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
30 June 2025				
Assets				
Segment assets	433	-	3,554	3,987
Liabilities				
Segment liabilities	(3,350)	-	(3,010)	(6,360)
Other information				
Amortisation	-	-	(8)	(8)
Depreciation	(36)	-	(187)	(223)
Group				
31 December 2024				
Assets				
Segment assets	438	-	3,466	3,904
Liabilities				
Segment liabilities	(2,601)	-	(2,766)	(5,367)
Other information				
Amortisation	-	-	(25)	(25)
Depreciation	(76)	-	(310)	(386)

5. Categories of financial instruments

Financial instruments as at the reporting date are as follows:

	Group		Company	
	30/06/2025	31/12/2024	30/06/2025	31/12/2024
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Financial assets</u>				
<i>At amortised cost</i>				
Trade receivables	927	593	-	-
Other receivables	359	408	941	967
Cash and bank balances	114	8	1	-
	<u>1,400</u>	<u>1,009</u>	<u>942</u>	<u>967</u>
 <u>Financial liabilities</u>				
<i>At amortised cost</i>				
Lease liabilities	1,178	1,283	102	104
Trade payables	857	742	-	-
Other payables	2,761	2,077	2,337	1,734
Deferred consideration	92	92	-	-
Amount due to directors	116	190	-	85
Loan from a director	774	399	682	307
Loan and borrowings	500	500	500	500
	<u>6,278</u>	<u>5,283</u>	<u>3,622</u>	<u>2,730</u>

6. Taxation

The Group calculates the period income tax credit/expense) using the tax rate that would be applicable to the expected total losses before tax. The major components of the income tax credit/expense) in the financial statements for the financial period ended 30 June 2025 and 30 June 2024 are as follows:

	Group	
	6 months ended	
	30/06/2025	30/06/2024
	S\$'000	S\$'000
<u>Continuing operations</u>		
Current income tax credit/ (expense)	-	-
Deferred tax credit relating to reversal of taxable temporary differences	(1)	(4)
Income tax credit/ (expense)	<u>(1)</u>	<u>(4)</u>

7. Dividends

No interim dividend for the period ended 30 June 2025 (30 June 2024: Nil) is recommended

8. Net Asset Value

	Group		Company	
	As at 30/06/2025 Cents	As at 31/12/2024 Cents	As at 30/06/2025 Cents	As at 31/12/2024 Cents
Net asset value per ordinary share	(0.1579)	(0.1070)	0.0820	0.1572

The calculation of net asset value per ordinary share was based on 1,502,938,302 shares as at 30 June 2025 (31 December 2024: 1,366,958,815).

9. Share capital

	30/06/2025		31/12/2024	
	No. of shares '000	Amount S\$'000	No. of shares '000	Amount S\$'000
Beginning of the financial period/year	1,502,938	46,364	933,802	42,745
Issuance of new ordinary shares	-	-	427,251	2,991
Issuance of new ordinary shares pursuant to the vesting of the awards granted under the Plan	-	-	141,885	741
Share issue expenses	-	-	-	(113)
End of the financial period/year	1,502,938	46,364	1,502,938	46,364

The Company had on 5 March 2024, allotted and issued 427,251,570 new ordinary shares pursuant to the loan capitalization at a price of \$0.007 per share.

The Company has an employee share performance plan under which options to subscribe for the Company's ordinary shares have been granted to certain directors and employees.

The Company had on 5 March 2024 and 19 June 2024, allotted and issued 16,000,000 and 125,884,658 new ordinary shares, respectively granted under the Plan at a price of \$0.007 and \$0.005 per share respectively.

The total number of issued shares excluding treasury shares was 1,502,938,302 as at 30 June 2025 and as at 31 December 2024

There were no treasury shares held as at 30 June 2025 and 31 December 2024.

There were no subsidiary holdings as at 30 June 2025 and 31 December 2024.

There were no sales, transfers, cancellations and/or use of treasury shares or subsidiary holdings as at 30 June 2025 and 31 December 2024.

10. Subsequent Event

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

Other Information Required by Listing Rule Appendix 7.2

1. **Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

These figures have not been audited or reviewed by the auditors.

2. **Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).**

Not applicable.

3. **If the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion, to include:**

- (a) **Updates on the efforts taken to resolve each outstanding audit issue**
- (b) **Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. The Group and the Company have received an unmodified audit opinion in the recent audited financial statements.

4. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:**

- (a) **any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**

REVIEW OF TURNOVER, COSTS AND EARNINGS**Continuing operations*****Revenue***

The Group's revenue increased by S\$0.14 million, from S\$0.68 million for the 3-month period ended 31 June 2024 ("**1H2024**") to approximately S\$0.82 million for the 3-month period ended 31 June 2025 ("**1H2025**"). In 6M2025, the Group's revenue increased by approximately S\$0.38 million to S\$1.77 million as compared to S\$1.39 million in 6M2024. The increase primarily arose from franchise fee income of approximately S\$0.31 million from the Corporate and Healthcare wellness education segment, which had no contribution in 6M2024, and an improvement of approximately S\$0.07 million in the Healthcare products and services segment. This overall growth reflects stronger performance across the Group's operating segments, supported by higher market demand, product innovation, and strategic partnerships.

Gross profit

The Group's gross profit for 6M2025 increased by S\$0.38 million to S\$0.82 million, as compared to 6M2024. This improvement is primarily attributable to the franchise fee income earned from the Corporate and Healthcare wellness education segment. The segment contributed revenue of S\$0.31 million in 6M2025, whereas no such income was recorded in the corresponding period of the previous year. As there is no cost of sales associated with the franchise fee, the full amount contributed directly to gross profit, resulting in an overall increase in the gross profit margin for 6M2025. In addition, the Healthcare products and services segment also recorded stronger gross profit, supported by increased sales of high-margin consumables and improved cost efficiency.

Other operating income

The Group's operating income for 1H2025 decreased by S\$235,000 to S\$18,000 as compared to 1H2024. In 6M2025, the Group's operating income decreased by S\$245,000 to S\$49,000 as compared to 6M2024. The decrease from 1H2024 arose from decrease in government grant, liabilities written off and reversal of accruals.

Selling and distribution expenses

Selling and distribution expenses decreased by S\$122,000, from S\$261,000 in 1H2024 to S\$139,000 in 1H2025. In 6M2025, the selling and distribution expenses decreased by S\$85,000 to S\$285,000 as compared to 6M2024. The decrease was primarily attributable to a reduction in promoter-related expenses, following the Group's decision to streamline manpower deployment in sales and marketing functions. This initiative aimed to optimise workforce allocation and avoid redundant headcount, while maintaining effectiveness in brand visibility and market reach.

Administrative expenses

Administrative expenses increased by S\$60,000 from S\$689,000 in 1H2024 to S\$749,000 in 1H2025. The increase was primarily due to additional product registration costs incurred in relation to healthcare product submissions for government tenders as well as the ISO audit fees incurred in June 2025. In 6M2025, the administrative expenses decreased by S\$30,000, from S\$1,498,000 to S\$1,468,000. The decrease was mainly attributable to lower courier and logistics charges during the period, following improvements in internal coordination and shipping consolidation.

Finance costs

The Group's finance costs increased by S\$2,000, from S\$13,000 in 1H2025 to S\$15,000 in 1H2025. In 6M2025, the Group's finance costs increased by S\$9,000, from S\$22,000 in 6M2024 to S\$31,000 in 6M2025. These finance costs are mainly attributable to the interest expense related to the lease liabilities.

Loss for the financial period from continuing operations

As a result of the above, the Group reported a loss of S\$0.67 million in 1H2025 as compared to a loss of S\$0.65 million in 1H2024. In 6M2025, the Group reported a loss of S\$0.91 million as compared to a loss of S\$1.16 million in 6M2024. The reduced loss reflects the Group's ongoing efforts and commitment to strengthening its presence in the healthcare sector through the implementation of its integrated solutions strategy, positioning the business for sustainable long-term growth.

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

REVIEW OF WORKING CAPITAL, ASSETS AND LIABILITIES*Non-current assets*

Non-current assets decreased by S\$0.20 million, from S\$1.67 million as of 31 December 2024 to S\$1.47 million as of 30 June 2025. The decrease was mainly attributable to depreciation charges of S\$0.05 million for plant and equipment and S\$0.15 million for right-of-use assets.

Current assets

Current assets increased by S\$0.28 million, from S\$2.24 million as of 31 December 2024 to approximately S\$2.52 million as of 30 June 2025. This increase was mainly driven by a rise in cash and cash equivalents of S\$0.11 million and an increase in trade and other receivables of S\$0.31 million, partially offset by a decrease in inventories of S\$0.14 million. These movements are in line with increases in revenue in 6M2025.

Current liabilities

Current liabilities increased by approximately S\$0.62 million, from S\$3.36 million as of 31 December 2024 to S\$3.98 million as of 30 June 2025. The increase was mainly driven by a S\$0.80 million rise in trade and other payables, partially offset by the repayment of lease liabilities amounting to S\$0.10 million and the repayment of S\$0.08 million due to directors.

Non-current liabilities

Non-current liabilities increased by approximately S\$0.37 million, from S\$2.01 million as of 31 December 2024 to S\$2.38 million as of 30 June 2025. This was due to a loan of S\$0.37 million from a director, which has been classified under non-current liabilities.

REVIEW OF CASH FLOW STATEMENT*Net cash used in operating activities*

In 6M2025, the Group recorded a net cash outflow for operating activities of S\$0.23 million. The net operating cash outflow was mainly due to operating losses before working capital changes of S\$0.68 million, adjusted for working capital inflow of S\$0.45 million. The working capital inflow is mainly due to (i) a decrease in inventories of S\$0.14 million, (ii) an increase in trade and other receivables of S\$0.31 million and (iii) a increase in trade and other payables of S\$0.62 million.

Net cash generated from financing activities

Net cash generated from financing activities of S\$0.34 million in 6M2025 arose mainly from proceeds from loans from a director of S\$0.47 million, offset by the payment for principal and interest of lease liabilities of S\$0.13 million.

- 5. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not applicable.

6. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

The healthcare sector continues to face these challenges: digital transformation, cost pressures, supply chain uncertainties partially caused by USA tariff imposition. To address these challenges in the next 12 months, the Company is implementing proactive mitigation measures with our manufacturing partners, including alternative sourcing strategies and inventory optimisation. Our operational focus remains on stabilising core offerings through the On Call Diabetes Management Platform and key medical device lines, while improving portfolio efficiency.

The Company is adapting its commercial approach through closer collaboration with healthcare providers and institutional partners. This includes optimising pricing matrices for PHI National Contracts, developing bundled solutions for aged care facilities, and implementing dynamic pricing for private hospitals. By strengthening partner relationships and optimising our supply network, we aim to maintain service reliability while controlling operational costs.

Looking ahead, the Company will concentrate on operational resilience through strategic inventory management and leaner processes. Our deep understanding of Singapore's healthcare needs and established partner ecosystem position us to respond effectively to industry challenges. We remain committed to delivering quality solutions while adapting to this dynamic business environment.

7. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on?

None.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

None.

(c) Whether the dividend is before tax, net of tax or tax-exempt?

Not applicable.

(d) Date payable

Not applicable.

(e) Books closure date

Not applicable.

8. If no dividend has been declared/recommended, a statement to that effect.

No dividend has been declared or recommended for the year ended 30 June 2025 in view that the Group is loss-making and focusing on expanding its business operations, in particular the Group's healthcare products and services segment.

9. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group has not obtained a general mandate for the IPTs from the shareholders.

10. Confirmation that the interim financial statements not false or misleading in any material aspect in pursuant to Rule 705(5) of the Listing Manual.

The Board of Directors hereby confirms that, to the best of its knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited financial statements for the six-month period ended 30 June 2025 to be false or misleading in any material aspect.

11. Confirmation that the issuer has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7H under Rule 720(1) of the Listing Manual).

The Company hereby confirms that it has already procured undertakings from all its Directors and executive officers in the format set out in Appendix 7H under Rule 720(1) of the Catalist Rules.

12. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with any director, CEO or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Zhang Yulei	38	Ms. Zhang Yulei is the daughter of Dr. Zhang Jian, the Chairman and Executive Director of the Company. He is also a substantial shareholder of the Company.	Chief Strategy Officer of the Company	No changes

BY ORDER OF THE BOARD

ZHAO XIN
CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
7 August 2025